title: Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
authors.affiliation: Istituto di Clinica delle Malattie Infettive, Università Cattolica del S. Cuore, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: De Luca
authors.forename: F
authors.initials: F
authors.lastname: Baldini
authors.forename: A
authors.initials: A
authors.lastname: Cingolani
authors.forename: S
authors.initials: S
authors.lastname: Di Giambenedetto
authors.forename: M
authors.initials: M
authors.lastname: Zaccarelli
authors.forename: V
authors.initials: V
authors.lastname: Tozzi
authors.forename: A
authors.initials: A
authors.lastname: Ammassari
authors.forename: R
authors.initials: R
authors.lastname: Murri
authors.forename: A
authors.initials: A
authors.lastname: Antinori
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D019829:Nevirapine / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine